Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.440
-0.060 (-4.00%)
At close: Oct 29, 2024, 4:00 PM
1.560
+0.120 (8.33%)
After-hours: Oct 29, 2024, 5:56 PM EDT

Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.

Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Chemomab Therapeutics Ltd.
Chemomab Therapeutics logo
Country Israel
Founded 2004
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Adi George

Contact Details

Address:
Building 7, Kiryat Atidim
Tel Aviv, 6158002
Israel
Phone 972 77 331 0156
Website chemomab.com

Stock Details

Ticker Symbol CMMB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534248
CUSIP Number 03280X102
ISIN Number US16385C1045
Employer ID 81-3676773
SIC Code 2834

Key Executives

Name Position
Dr. Adi Mor George Ph.D. Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director
Sigal Fattal CPA, M.B.A. Chief Financial Officer
Dr. Matthew B. Frankel M.B.A., M.D. Chief Medical Officer and Vice President of Drug Development
Barbara Lindheim Consulting Vice President of Investor and Public Relations, Strategic Communications
Jack Lawler Senior Vice President of Global Clinical Development Operations

Latest SEC Filings

Date Type Title
Oct 11, 2024 6-K Report of foreign issuer
Sep 16, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 12, 2024 144 Filing
Sep 9, 2024 424B3 Prospectus
Sep 6, 2024 EFFECT Notice of Effectiveness
Aug 29, 2024 UPLOAD Filing
Aug 23, 2024 F-3 Filing
Aug 21, 2024 6-K Report of foreign issuer
Aug 20, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 9, 2024 D Notice of Exempt Offering of Securities